WINNIPEG, MANITOBA--(Marketwire - March 04, 2008) - DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes is pleased to announce that it has received regulatory clearance in the European Union to conduct a Phase II human study with DM-99 in type 2 diabetes patients.
